Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Phase III Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) With Alteration in 5q- and Anemia Without the Need of Transfusion.

NCT01243476 is registered in ClinicalTrials.gov with Fundación General de la Universidad de Salamanca as lead sponsor.

NCT NCT01243476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01243476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Phase III Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) With Alteration in 5q- and Anemia Without the Need of Transfusion.
Lead sponsor
Fundación General de la Universidad de Salamanca
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2010
Completion date
June 6, 2022
Enrollment
61 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome